NIP
ALXN

Nicholas Investment Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Nicholas Investment Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,974
Closed -$226K – 194
2020
Q3 		$226K Buy
+1,974
New +$213K 0.02% 168

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Nicholas Investment Partners's ALXN Position: Q4 2020 in Review

Nicholas Investment Partners sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 1,974 shares — an estimated $226K sold.

Nicholas Investment Partners first reported a position in ALXN in Q3 2020 and held it in 1 quarter. The position peaked at $226K in Q3 2020. 824 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Nicholas Investment Partners reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Nicholas Investment Partners sold 1,974 Alexion Pharmaceuticals shares in Q4 2020, an estimated $226K.
  • Nicholas Investment Partners first reported a position in Alexion Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Nicholas Investment Partners's Alexion Pharmaceuticals position peaked at $226K in Q3 2020.
  • 824 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Nicholas Investment Partners's 13F filing for Q4 2020, filed 11 Feb 2021.